Eligibility NCT00662714 Cystic Fibrosis

Alter mindestens 10 Jahre

Ja

Nein

Diagnosed cystic fibrosis

Ja

Nein

Newly diagnosed Diabetes mellitus in the screening

Ja

Nein

Diabetic keto-acidosis (blood glucose > 350 mg/dl and arterial pH < 7.25)

Ja

Nein

Already treated Diabetes mellitus by oral antidiabetic medication or insulin

Ja

Nein

Systemic steroid therapy during the last 3 months

Ja

Nein

Transplantation (status post TX or on the waiting list for TX)

Ja

Nein

Beginning pulmonary insufficiency, FEV1 < 35% at pulmonary function test in stable condition

Ja

Nein

Schwangerschaft

Ja

Nein

Already diagnosed and treated diabetes mellitus

Ja

Nein

Patients with diabetic keto-acidosis (blood glucose > 350 mg/dl and arterial pH < 7.25) with or without diabetic coma

Ja

Nein

Severe liver insufficiency (chronic hepatitis B, AST or ALT twice the upper limit of normal, Quick's value < 70% which is a contraindication to use Repaglinide)

Ja

Nein

Treatment with an indispensable important drug which contraindicates Repaglinide

Ja

Nein

PEG/ gastric tube/ total parenteral alimentation for more than 4 weeks during the study

Ja

Nein

CF-patients with type 1 diabetes

Ja

Nein

Not patient's consent to randomisation and therapeutic trial

Ja

Nein

Participation on other medical trial

Ja

Nein